Nuvation Bio Inc. Class A (NUVB)
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 4.85 -0.14%
NUVB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.71B
- EPS (TTM)
- -$0.44
- Dividend yield
- None
- 52-week range
- 3.36 – 9.75
- Day range
- 4.79 – 4.95
- Volume / Avg
- 5.45M / 5.73M
- Beta
- —
- Shares outstanding
- 350.12M
- Next earnings
- Nov 2, 2026
52-week range
NUVB stock today
Nuvation Bio (NUVB) closed at $4.86 on Oct 7, down 0.41% (-$0.02), versus the S&P 500's 0.22% decline. Shares are 50.2% below their 52-week high of $9.75, set on Dec 22, 2025 and 44.6% above the 52-week low of $3.36, in the middle of the past year's range. NUVB is down 45.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 32.8%.
Nuvation Bio has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful. Nuvation Bio's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Nuvation Bio
Company profileNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David T. Hung M.D.
- Headquarters
- New York, NY
- Employees
- 305
- IPO year
- 2020
- Website
- nuvationbio.com
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$13.00+167.49%
- Strong buy 3
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $-0.12
Nuvation Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GENBGenerate Biomedicines Inc. | 13.57 | -1.67% | $1.74B | vs NUVB |
| SEPNSepterna Inc. | 36.00 | +0.93% | $1.68B | vs NUVB |
| BRVEBraveheart Bio Inc. | 18.58 | -6.11% | $1.67B | vs NUVB |
| ANIPANI Pharmaceuticals Inc. | 71.93 | +0.57% | $1.65B | vs NUVB |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs NUVB |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs NUVB |
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.69 | +1.12% | $1.62B | vs NUVB |
| QUREuniQure N.V. | 23.14 | +0.35% | $1.61B | vs NUVB |
Indexes, lists and sector
Nuvation Bio stock FAQ
What is Nuvation Bio's stock price today?
NUVB last traded at $4.86 as of Oct 7, 4:00 PM EDT, down 0.41% on the day. Prices are delayed at least 15 minutes.
When is Nuvation Bio's next earnings date?
Nuvation Bio is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $-0.12.
Who is Nuvation Bio's CEO?
Dr. David T. Hung M.D. is the chief executive officer of Nuvation Bio Inc. Class A, which has about 305 employees.
What is the NUVB 52-week high?
The 52-week high for NUVB is $9.75 and the 52-week low is $3.36. The stock is currently 50.2% below its high.